Market Overview

Endometriosis | A Drug Pipeline Analysis Report 2018 | Technavio

Share:

Technavio has announced their latest pipeline analysis report on the
drug pipeline for endometriosis.
The report includes a detailed analysis of the pipeline molecules under
investigation within the defined data collection period to treat
endometriosis.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180809005651/en/

Technavio has published a new report on the drug development pipeline for endometriosis, including a ...

Technavio has published a new report on the drug development pipeline for endometriosis, including a detailed study of the pipeline molecules. (Photo: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Endometriosis: Market overview

Endometriosis is a condition in which cells similar to the cells in the
endometrium (tissue layer that normally covers the inner part of the
uterus) grow outside the uterus. Endometriosis is not followed by any
symptoms, but sometimes, it leads to painful menstruation, lower
abdominal pain, or pain during sexual intercourse. It can also lead to
infertility.

According to a senior market research analyst at Technavio, "The main
areas where endometriosis occurs are within the fallopian tubes, outside
the fallopian tubes and ovaries, the outer surface of the uterus and
intestines, and on the surface of the pelvic cavity. It is very rarely
found on the surface of the liver, old scars, lungs, or the brain."

Endometriosis: Segmentation analysis

This pipeline analysis report segments the endometriosis market based on
therapies employed (monotherapy and combination therapy), RoA (oral,
intramuscular, intravaginal, and subcutaneous), therapeutic modality
(small molecule, peptide, fusion protein, monoclonal antibody and
vaccine), targets (GnRH receptor, AKR1C3, P2X3R, progesterone receptor,
and others), MoA (GnRH receptor agonist, AKR1C3 inhibitor, P2X3R
antagonist, and others), geographical segmentation (Japan, Italy,
Hungary, The Czech Republic, US, Poland, and others) and recruitment
status (active, not recruiting, not yet recruiting, and recruiting). It
provides an in-depth analysis of the prominent factors influencing the
market, including drivers, opportunities, trends, and industry-specific
challenges.

Based on therapeutic modality, around 46% of the molecules that are
being investigated for the treatment of endometriosis are small
molecules. These molecules are chemically manufactured active substances
that enter cells easily due to their low molecular weight.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!